Skip to main content

Investor Relations

We aim at sustaining a continuous, clear and trustful communication with all our partners and stakeholders.

Integrated diagnostic solutions for critical care settings

We are committed to improving patient outcomes with innovative diagnostic solutions for acute care that allow the diagnosis, outcome prediction, and monitoring of patients with acute medical conditions.

SphingoTec develops and markets innovative in vitro diagnostics solutions for novel and proprietary blood-based protein biomarkers. Our aspiration is to effectively translate scientific advancements to routine clinical practice. We develop biomarkers addressing diagnostically underserved critical care conditions such sepsis, acute heart failure, acute kidney injury, and cardiogenic shock.

SphingoTec is a privately held company with the headquarter in Hennigsdorf near Berlin and with a wholly owned subsidiary in San Diego, USA. We have a long history of biomarker discovery, development and validation at our German location. Our U.S. location is home to the production of our fully developed Point of Care testing platform Nexus IB10.


Our investors share our vision of improving patient outcomes

SphingoTec in a nutshell

Our portfolio of tests supports a better management of critically ill patients, where fast and reliable information is essential in taking treatment decisions. We are a fully integrated diagnostics company: our innovative biomarkers are commercially available on the point of care platform Nexus IB10.

The assay portfolio for near patient testing goes beyond innovation: on the Nexus IB10 platform, clinicians can deploy a wide range of commonly used parameters in acute and critical care settings, making the analyzer a useful addition to intensive care units (ICU), emergency departments (ED), and other near patient settings.

Investment Thesis


A unique platform

A rapid point-of-care platform that is a bed-side solution to diagnostic healthcare challenges.

Early stage opportunity

An opportunity of investment in more than 200 patents that could benefit over 60 million patients worldwide.

Skillful team

A skilled international team with a broad scope of experience committed to improve patient lives

An innovative portfolio

Innovative biomarkers for diagnosis, prediction and monitoring of ICU mortality drivers.

Latest News

11. April 2022
Diagnostics company SphingoTec GmbH announced the implementation of two critical care biomarkers to guide the application of a potential new drug candidate for the treatment of COVID-19 patients.
Read more
24. March 2022
The diagnostic company SphingoTec GmbH announces new evidence supporting the use of innovative biomarkers in the early identification of organ dysfunction and risk stratification of cardiac surgery patients.
Read more
17. March 2022
SphingoTec and Rivaara Labs today announced that they have entered into a multi-year distribution agreement for the commercialization of SphingoTec’s point of care diagnostic solutions in the Indian subcontinent.
Read more

Events & Expos

30. November - 02. December 2022

13:08 - 15:10

Hamburg, Germany
The DIVI is the largest event for emergency and intensive care medicine in German-speaking countries. We look forward to once again be exhibiting.
Read more
06. - 09. October 2022

06:55 - 06:59

Berlin, Germany

The Forum Nephrologie is a scientific, educational, and networking meeting and part of the 14. Jahrestagung der DGfN. The main congress program will kick off with an opening ceremony on Thursday,…

Read more
22. - 23. July 2022

08:10 - 10:14

Munich, Germany
The biennial event aims to provide continuing education on all aspects of clinical nephrology: regular topics include hypertension, glomerulonephritis, renal replacement procedures and their complications, renal transplantation, CKD-MBD, and interfaces with other disciplines.
Read more

Contact Investor Relations

Do you have any questions or require more information? Please contact the Investor Relations Team, send us an e-mail or call us.

phone: + 49 (0)330 220 56 5 - 0

Dr. Angelo Moesslang

Chief Financial Officer and Managing Director

Subscribe to our Newsletter

Follow the link below to subscribe to our Newsletter & receive updates on our company and products

Subscribe now